Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aminosilverlactone B mesylate
- Development stage
- Unknown
- Lead developer
- Jiangsu Kefeiping Pharmaceutical
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Aminosilverlactone B mesylate is a small molecule derivative of ginkgolide B, a natural terpene lactone found in *Ginkgo biloba*. Developed by Jiangsu Ke Feiping Pharmaceutical, the drug is designed as a potent platelet-activating factor (PAF) receptor antagonist for the treatment of acute ischemic stroke. By blocking the PAF receptor, it inhibits PAF-induced platelet aggregation, leukocyte activation, and inflammatory responses, which are key contributors to neuronal damage following an ischemic event. The drug is formulated as an injection for intravenous administration and has been evaluated in Phase 1 clinical trials for safety, tolerability, and pharmacokinetics.
- Other names
- aminoginkgolide B mesylate胺银内酯B甲磺酸盐甲磺酸胺银内酯B
02
Targets
PTAFR (Platelet-activating factor receptor)
Beyond the preview
Go deeper on aminosilverlactone B mesylate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aminosilverlactone B mesylate.